Skip to main content
. 2017 Dec 16;2017(12):CD011300. doi: 10.1002/14651858.CD011300.pub2
Methods An USA prospective randomised trial
Participants Number of participants: 88 Number randomised: Experimental group (BCG‐treated + surgery): 48 Control group (Control subjects + surgery): 40 Number evaluated: Experimental group: 48, age (Mean ± SD): 61 ± 9 years Control group: 37, age (Mean ± SD): 61 ± 10 years Diagnosis: Patients with potentially resectable non‐small cell carcinoma of the lung Inclusion: Patients suspected of having lung cancer were excluded if a definite diagnosis had not been established before thoracotomy.
Interventions Experimental group : Injecting BCG 10⁷ viable organisms for PPD skin test‐negative participants and 5x10⁶ for PPD‐positive participants into the tumour mass. Then underwent thoracotomy 2 to 3 weeks after intratumoural injection of BCG.
Control group: All control participants underwent thoracotomy immediately following randomisation.
A 12‐week course of 300 mg INH daily was given to all participants.
Outcomes Duration of follow‐up (median ± SD): experimental group: 986 ± 412 days; control group: 1062 ± 390 days
OS, Median time to recurrence
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Stratified block randomisation method."Patients were divided into 2 groups according to a table of random numbers and sealed‐envelope technique in strict numerical order of entry"
Allocation concealment (selection bias) Low risk "Patients were divided into 2 groups according to a table of random numbers and sealed‐envelope technique in strict numerical order of entry"
Blinding of participants and personnel (performance bias) All outcomes High risk Open‐label design
Blinding of outcome assessment (detection bias) All outcomes Unclear risk Not described
Incomplete outcome data (attrition bias) All outcomes Low risk 85 randomised participants were included in analysis (96.6%)
Selective reporting (reporting bias) High risk No prior protocol was available, and no pre‐specified primary outcome was reported.
Other bias Low risk No obvious potential source of bias